Cedars Sinai 5th Annual Cedars-Sinai Gastrointestinal Tumor Conference 2024

Overview

The Cedars Sinai 5th Annual Cedars-Sinai Gastrointestinal Tumor Conference 2024 offers a comprehensive update on the latest research and therapeutic advances in gastrointestinal cancers. This conference includes presentations covering precision medicine, immunotherapy, and biomarker strategies for cancers of the pancreas, liver, and gastroesophageal tract, as well as neuroendocrine and rare tumors.

On-demand gastroenterology education — accessible anytime, anywhere.

Format: 2 videos, 10 PDFs
Total size: 3.88 GB

Agenda

This conference delivers continuous video recordings from the live event, featuring expert lectures and panel discussions on current clinical and research topics in GI oncology.

• Introduction — Andrew E Hendifar, MD; Arsen Osipov, MD; Jun Gong, MD
• Molecular Landscape in CRC: Shaping the Future — Marwan Fakih, MD
• The Challenges of Treating Pancreatic Cancer — Philip Philip, MD
• Cholangiocarcinoma and HCC — Anthony El-Khoueiry, MD
• Update in Surgical Management of Gastric Cancer — Miguel Burch, MD
• Panel Discussion: GI Cancer Cases — Anthony El-Khoueiry, MD; Edward Wolin, MD; Philip Philip, MD; Emily Nachtigal, MD; Vi K. Chiu, MD, PhD; Kambiz Kosari, MD
• Break and Exhibits
• Novel Approaches to Targeting Amino Acid Metabolism and the PI3K Pathway in Cancer — Oliver DK Maddocks, MPharm, PhD
• Cedars Sinai Cancer: Molecular Twin — Dan Theodorescu, MD, PhD
• How I Approach TNT in Rectal Cancer — Katelyn Atkins, MD, PhD
• Management Updates in Neuroendocrine Tumors 2024 — Edward Wolin, MD
• Pick Up Lunch and Exhibits
• Immunotherapy for GI Cancer — Joel R Hecht, MD
• Role of Social Media in Oncology Today — Tatiana Prowell, MD
• Closing Remarks — Andrew E Hendifar, MD

Objectives

1. Consider advances in biomarkers and therapy to better inform treatment decision-making for patients with gastroesophageal cancers
2. Use AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence-based national guidelines for treatment planning
3. Evaluate the basic science of immune therapy for GI malignancies and the implications for transfer from bench to bedside
4. Increase knowledge of therapy for neuroendocrine tumors and biomarker identification of novel therapies
5. Identify and implement optimal strategies for managing therapy-related side effects and toxicities in patients treated with therapeutic agents
6. Anticipate the needs, problems, and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families, and the healthcare team

Speakers

• Andrew E Hendifar, MD
• Arsen Osipov, MD
• Jun Gong, MD
• Marwan Fakih, MD
• Philip Philip, MD
• Anthony El-Khoueiry, MD
• Miguel Burch, MD
• Edward Wolin, MD
• Emily Nachtigal, MD
• Vi K. Chiu, MD, PhD
• Kambiz Kosari, MD
• Oliver DK Maddocks, MPharm, PhD
• Dan Theodorescu, MD, PhD
• Katelyn Atkins, MD, PhD
• Joel R Hecht, MD
• Tatiana Prowell, MD

Target Audience

This conference is intended for physicians and advanced practice providers specializing in Endocrinology & Metabolism, Family / General Medicine, Gastroenterology, Hepatology, Internal Medicine, Medical Genetics, Nuclear Medicine, Oncology, Pain Management, Palliative Care, Pathology & Laboratory Medicine, Radiation Oncology, and Radiology. It is also relevant for non-physician healthcare professionals involved in gastrointestinal cancer care.

Why This Topic Matters

The Cedars Sinai 5th Annual Cedars-Sinai Gastrointestinal Tumor Conference 2024 addresses critical advances in gastrointestinal oncology, a specialty with rapidly evolving treatment paradigms. By covering biomarkers, immunotherapy, and precision medicine, this conference strengthens clinical decision-making for healthcare professionals managing GI cancer patients.

MedHub Central provides access to this specialized gastroenterology content, supporting continuous professional development and enhancing the expertise of clinicians managing complex gastrointestinal malignancies.